



S0040-4039(96)00601-6

Biosynthesis of Tetronasin: Part 7. Preparation of Structural Analogues of the Tetraketide Biosynthetic Precursor to Tetronasin

Simon L. Less,^a Peter F. Leadlay,^c Christopher J. Dutton^b and James Staunton.^{a*}


^a Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, U.K.

^b Central Research Division, Pfizer Ltd., Sandwich, Kent CT13 9NJ, U.K.


^c Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, U.K.

Abstract: The preparation of three structural analogues of the putative tetraketide biosynthetic precursor (2) of the acyl tetronic acid ionophore tetronasin, as *N*-acetylcysteamine thioesters (3), (4) and (5) is described. Two examples are ¹⁹F-labelled. Copyright © 1996 Elsevier Science Ltd

In a preceding letter¹ we discussed incorporation experiments which involved structural analogues of the proposed di-, tri- and tetraketide intermediates on the biosynthetic route to the ionophore antibiotic tetronasin (1).² These experiments probed the substrate specificity of the polyketide synthase by attempting to produce tetronasin analogue metabolites, shown in Scheme 1. Here we report the synthetic routes used to prepare, as *N*-acetylcysteamine thioesters, the three analogues (3), (4) and (5) of the proposed tetraketide precursor (2) that were required for our studies, as their *N*-acetylcysteamine thioesters. The syntheses of the diketide and triketide analogues are described elsewhere.³




The retrosynthetic analysis, shown in Scheme 2, required a π -facially selective *anti*-aldol reaction to create the absolute stereochemistry at centres C-2 and C-3. Aldehydes corresponding to synthon (6) were accessible from intermediates (7), (8) and (9), shown in Scheme 3, each of which lies on the synthetic route to a triketide analogue, described in the preceding letter.³




The aldehydes (10), (11) and (12)⁴ were obtained *via* reductive cleavage of oxazolidinone from compounds (7), (8) and (9) respectively, to give the corresponding alcohols, followed by oxidation using the Dess-Martin periodinane.⁵ Paterson's aldol methodology⁶ was employed in the preparation of the *anti*-aldol adducts (13), (14) and (15). This involved reacting the chiral boron *E*-enolates of the α' -benzoyloxy ketones (19) and (20), shown in Scheme 4, with the requisite aldehydes. Ketones (19) and (20) were prepared from (*S*)-ethyl lactate (17) *via* the appropriate Grignard attack on the derived Weinreb amide (18),⁷ immediately followed by addition of benzoic anhydride. On reaction with dicyclohexylboron chloride⁸ and dimethylethylamine, the presence of the benzoyl protecting group ensured formation of *E*-enol dicyclohexyl borinates. The *anti*-aldol products (13), (14) and (15) were formed with complete π -face selectivity (by ¹H n.m.r), and any Felkin-Ahn type influence from the chiral aldehyde helped to reinforce this selectivity. Subsequent steps in the synthesis involved hydrolysis of the benzoyl ester, then 1, 2-hydroxy ketone cleavage

by periodate⁹ to give the carboxylic acids (e.g. **16**), and finally coupling with *N*-acetylcysteamine using DCC-DMAP,¹⁰ to give the target analogues (**3**), (**4**) and (**5**).



Scheme 3: [a] (i) LiAlH_4 , Et_2O , 0°C (59%). (ii) 2 eq. Dess-Martin periodinane, CH_2Cl_2 (90%). (iii) added to -78°C boron enolate formed from (2*S*)-*O*-benzoyl-3-pentanone (**19**), dicyclohexylboron chloride, dimethylethylamine, Et_2O , 0°C (50%). (iv) K_2CO_3 , $\text{MeOH-H}_2\text{O}$ 5:1 (67%). (v) 6 eq. sodium periodate, $\text{MeOH-H}_2\text{O}$ 2:1 (72%). (vi) *N*-acetylcysteamine, DCC, DMAP, CH_2Cl_2 (66%). [b] conditions as [a] (i) (66%). (ii) (77%). (iii) (35%). (iv) (63%). (v) (96%). (vi) (80%). [c] conditions as [a] unless otherwise stated (i) (57%). (iii) (2*S*)-*O*-benzoyl-3-hexanone (**20**), dicyclohexylboron chloride, dimethylethylamine, Et_2O , 0°C (4%, over 2 steps). (iv) (36%). (v) (77%). (vi) (92%).



Scheme 4: (i) 2 eq. *N,O*-dimethylhydroxylamine.hydrochloride, 2 eq. AlMe_3 , CH_2Cl_2 , -10°C to 20°C (74%). (ii) 4 eq. EtMgCl , THF, 0°C , 2 h; then added to 8 eq. benzoic anhydride, 10 eq. diisopropylethylamine, 2 eq. DMAP, CH_2Cl_2 , 0°C to 20°C , 48 h (61%). (iii) 3 eq. *n*- PrMgCl , THF, 0°C , 2 h; then added to 6 eq. benzoic anhydride, 7 eq. diisopropylethylamine, 2 eq. DMAP, CH_2Cl_2 , 0°C to 20°C , 18 h (28%).

Acknowledgements: We thank the EPSRC and Pfizer Ltd (CASE studentship to SLL) for financial support.

References and Notes

- See a proceeding paper in this journal and references therein: *Biosynthesis of Tetronasin: Part 5. Novel Fluorinated and Non-fluorinated Analogues of Tetronasin via Intact Incorporation of Di-, Tri- and Tetraketide Analogue Precursors*.
- Davies, D. H.; Snape, E. W.; Suter, P. J.; King, T. J.; Falshaw, C. P. *J. Chem. Soc. Chem. Comm.*, **1981**, 1073.
- See the proceeding paper in this journal: *Biosynthesis of Tetronasin: Part 6. Preparation of Structural Analogues of the Diketide and Triketide Biosynthetic Precursors to Tetronasin*.
- All new compounds gave spectroscopic data in agreement with the assigned structures.
- (a) Dess, D. B.; Martin, J. B. *J. Am. Chem. Soc.*, **1991**, *113*, 7277. (b) 1, 1, 1-triacetoxy-1, 1-dihydro-1, 2-benzodioxol-3(1*H*)-one (the Dess-Martin periodinane) was synthesised according to the procedure of Ireland, R. E., Liu, L., *J. Org. Chem.*, **1993**, *58*, 2899.
- Paterson, I.; Wallace, J. W.; Velázquez, S. M. *Tetrahedron Lett.*, **1994**, *35*, 9083.
- (a) Levin, J. I.; Turos, E.; Weinreb, S. M. *Synth. Comm.*, **1982**, *12*, 989. (b) Nahm, S.; Weinreb, S. M. *Tetrahedron Lett.*, **1981**, *22*, 3815.
- Dicyclohexylboron chloride synthesised: monochloroborane.dimethylsulphide, 2 eq. cyclohexene, Et_2O , 20°C , 2 h (75%).
- Haines, A. H. *Methods for the Oxidation of Organic Compound*, Academic Press, **1988**, Chapter 7, 277.
- Neises, B.; Steglich, W. *Angew. Chem., Int. Ed. Engl.*, **1978**, *17*, 522.

(Received in UK 8 February 1996; accepted 29 March 1996)